ProteinLogic Attends JP Morgan 2020

CAMBRIDGE, UK (2020-01-17) – ProteinLogic, the biomarker discovery and exploitation company, has attended the JP Morgan Health week in San Francisco.

CEO Nicolas Huber, who represented the company, attended a number of industry events to promote the innovative diagnostic technology of the company. He held meetings with a number of potential commercial partners, who showed significant interest in supporting the company in bringing its leading TB asset to the market.

The company is actively following up on all the opportunities attending this event has presented.

ProteinLogic featured in GenomeWeb’s 360Dx Innovative test is considered of significance in the fight against TB

CAMBRIDGE, UK (2019-12-23) – ProteinLogic, the biomarker discovery and exploitation company, has been featured in GenomeWeb’s 360Dx diagnostics online, one of the leading diagnostics newsletters.

The article followed interviews with ProteinLogic’s CEO, Dr Nicolas Huber, and a clinical collaborator of the company representing ProteinLogic’s study consortium, Dr Marcelo Cordeiro-Santos, as well as other experts in the field of TB diagnosis. The results stated in the article refer to ProteinLogic’s extensive clinical validation of its novel, blood-based, host immune response diagnostic for the ruling-out of Active TB disease in cohorts of varied genetic background, also from patients co-infected with HIV. The article further discusses the critical need for such a test in the diagnostic arsenal, and how the ProteinLogic approach could have a significant impact in the fight to eradicate TB.

Dr Huber stated: “We are excited to be featured in such a prestigious online publication. This is testament to the significant work of ProteinLogic in TB, and our dedication to making a difference against this terrible disease. With the completion of our multi-site clinical validation that has definitively proven the clinical efficacy of our test, ProteinLogic’s work is building momentum towards a commercial release of our test to make it available to the clinical community. I would like to express my gratitude to our clinical collaborators across the globe, without whom our work would not have been possible.”

The full article can be found here (paywall).

ProteinLogic to present at BioSeed2020 Company selected by UKRI to be part of only 60 presenting companies

CAMBRIDGE, UK (2019-12-17) – ProteinLogic, the biomarker discovery and exploitation company, has been selected by UKRI to present at the prestigious BioSeed event.

BioSeed is an early-stage life-sciences investment event, which provides a platform for only 60 innovative early-stage Life Sciences companies to present to over 100 specialist investors. The pitching session is followed by extensive one-to-one partnering as well as networking opportunities.

Dr Nicolas Huber, CEO of ProteinLogic, commented: “The innovative work we have done at ProteinLogic, and its potential social impact, continuous to be recognised, both in the UK and abroad. We are particularly pleased of the continued support by Innovate UK – UKRI in promoting us as a company worthy of investment. We are looking forward to presenting our work to the wider investment community.”

BioSeed2020 is taking place on the 20th of January in London.

ProteinLogic selected to China Company to participate in UKRI Global Business Innovation Programme in precision medicine

CAMBRIDGE, UK (2019-11-29) – ProteinLogic, the biomarker discovery and exploitation company, has been selected to represent the UK on the UKRI Global Business Innovation Programme (GBIP) in precision medicine on a mission to China.

The GBIP is geared exclusively for Precision Medicine businesses working with technologies that enable early and accurate diagnosis to inform patient treatment, as well as the availability of targeted therapies. It aims to help innovative UK businesses develop relationships with partners in China, allowing them to gain a foothold in this market set for extensive growth. It is specifically meant to showcase the best of British science and to build international collaborative partnerships that deliver sustained economic and health benefits in both countries.

ProteinLogic was selected out of a large number of applicants due to its innovative ImmiPrint® technology and its applicability in Tuberculosis diagnosis, a major health issue in China. The company is one of only 15 participants selected for this year’s Programme.

Commenting on the news, Dr Nicolas Huber, CEO of ProteinLogic, stated: “We are very pleased that ProteinLogic has been selected to represent the UK in the prestigious GBIP mission to China. This is a key target market for our innovative diagnostic for Tuberculosis, and we are delighted by the recognition our technology and company have been getting in the fight against this terrible disease. We are looking forward to forming strong and long-lasting collaborations in China, particularly with commercial parties interested in commercializing our test in the region.”

The mission is scheduled for the end of February 2020, and will visit Shanghai and Wuxi.

ProteinLogic to present at the 50th Union World Conference, Hyderabad, India

CAMBRIDGE, UK (2019-10-21) – ProteinLogic, the biomarker discovery and exploitation company, will be presenting results of its novel ImmiPrint®-TB test at the 50th Union World Conference on Lung Health, to be held in Hyderabad, India.

Our prominent clinical collaborators will be presenting their findings on the use of  ImmiPrint®-TB as an active TB disease rule-out test in high prevalence settings during the “Late-Breaker Session on TB” on Saturday the 2nd of November 2019.

ProteinLogic Attends the 71st AACC Meeting

CAMBRIDGE, UK (2019-08-06) – ProteinLogic, the biomarker discovery and exploitation company, is attending the 71st annual scientific meeting & clinical lab Expo of the American Association of Clinical Chemistry (AACC).

Dr Nicolas Huber, CEO of ProteinLogic, commented: “The AACC meeting, with its exclusive focus on laboratory diagnostics, is the most prestigious meeting to be attending in the space. Our presence here creates new opportunities for ProteinLogic for strategic collaborations with established IVD manufacturers with an interest in our assets and platform technology. Further, it allows us to stay abreast of the current thinking and developments in the field of laboratory science.”

ProteinLogic Completes Multi-Site Clinical Study on TB, Reports Results Exceeding WHO Requirements

CAMBRIDGE, UK (2019-08-01) – ProteinLogic, the biomarker discovery and exploitation company, today announces the completion of its multi-site study on the use of its novel diagnostic technology, ImmiPrint®, for the ruling-out of Active Tuberculosis (TB) disease from a blood sample.

Previously, the company had shown that its ImmiPrint  technology could achieve the requisite clinical accuracy in a significant internal study of approximately 1000 clinical samples on laboratory-grade immunoassay platforms.

Under an EU Horizon 2020 grant (ADVANTAGE 666308), the company built on this work and commissioned clinical studies for the collection of further blood samples from subjects suspected of Active TB disease. Prospective samples were collected from TB clinics in Brazil, South Africa, Spain and the UK. The tested combined cohort from all sites comprised 1343 genetically diverse clinical samples.

ProteinLogic’s test exceeded the WHO-mandated clinical performance of 90% and 70% sensitivity and specificity respectively. In particular, sensitivity was 91%, specificity was 75%, and Negative Predictive Value (NPV), a key measure for a rule-out test, was 94%. Such results have not been reported to date from a blood test from cohorts of mixed backgrounds, as immunoassay approaches have traditionally been optimized on local populations and do not apply well to different genetic backgrounds. Importantly, these results were obtained from analysis of the samples on a new immunoassay measurement device that could potentially be used at the Point-Of-Care, proving that the ImmiPrint technology is transferrable across platforms.

Dr Nicolas Huber, CEO of ProteinLogic, commented: “The results from our latest, multi-site study prove conclusively that ProteinLogic has achieved a significant milestone, not only as complete clinical validation of its ImmiPrint technology in TB, a very difficult to diagnose disease, but also in the development of a diagnostic test with the ability to support the fight against this deadly disease. Having built evidence of the applicability of our novel approach across measurement platforms, we are confident we are entering the market with a diagnostic solution that is readily adoptable in settings where it is needed most, and are looking forward to expanding our technology to other indications”.

ProteinLogic is preparing publications of these results in peer-reviewed journals.

The company would like to thank the EU for the support of its work through the Horizon 2020 grant mechanism. The company would also like to thank its clinical collaborators across the globe for their support in this study.

ProteinLogic Appoints Dr Adrian Woolfson as Non-Executive Director

CAMBRIDGE, UK (2019-06-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Adrian Woolfson as Non-Executive Director.

Dr Woolfson is the founder of ProteinLogic, having discovered soluble Cluster of Differentiation antigens that underpin ProteinLogic’s platform technology.

He is currently serving as Executive Vice President of Research & Development, Sangamo Inc., CA, USA. Dr. Woolfson has over a decade of biopharmaceutical industry experience in drug discovery, medical affairs and early and late stage clinical development. Previously, he served as Chief Medical Officer at Nouscom AG, a genetic cancer vaccine biotechnology company based in Basel, Switzerland, where he led the development of the company’s off-the-shelf and personalized neoantigen vaccine and oncolytic virus strategy. Prior to Nouscom, Dr. Woolfson served as Global Clinical Leader, Early and Late Stage Immuno-Oncology/Hematology at Pfizer Inc. in New York, and was responsible for defining Pfizer’s hematology immuno-oncology strategy and building its immuno-oncology hematological malignancies portfolio. Prior to that he was the Global Lead for Pfizer’s SMO inhibitor glasdegib, which received FDA approval in 2018. From 2007 to 2013, Dr. Woolfson held roles of increasing responsibility at Bristol-Myers Squibb, including Global Medical Lead for a first-in-human CDC7 inhibitor and selective JAK2 inhibitor.

Dr. Woolfson completed his post-graduate training in internal medicine at Addenbrooke’s Hospital, Cambridge, UK. He holds a BM BCh degree in Clinical Medicine from Oxford University and completed his PhD in molecular immunology at Cambridge University. He was the Charles and Katherine Darwin Research Fellow at Darwin College Cambridge, and a Wellcome Trust Clinical Research Fellow. He completed his doctoral and post-doctoral work in the laboratory of Nobel Prize winner and inventor of monoclonal antibodies Dr César Milstein in the Division of Protein and Nucleic Acid Chemistry at the MRC Laboratory of Molecular Biology in Cambridge, UK.

Dr Nicolas Huber, CEO of ProteinLogic, said: “We are delighted to have Dr Woolfson, the founder of ProteinLogic, back on the company board. He is joining at a turning point for the company as we have entered a commercial phase with our first clinically validated asset for the diagnosis of Tuberculosis. His extensive expertise in the field will be crucial to guiding ProteinLogic through its first commercial endeavours. His vision will ensure that the long-term direction of the company is on a firm footing for growth, beyond Tuberculosis into other indications of significant medical need. We are excited to welcome him back on board”.

ProteinLogic has patent granted in USA and EU, files 2nd patent Company expands presence in the TB biomarker space

ProteinLogic (PL), the biomarker discovery and exploitation company, has received approval for granting of its first patent in biomarkers for the diagnosis of Tuberculosis in the USA and the EU.

At the same time, the company has filed a 2nd patent in the same space. This new patent allows the company to expand the applicability of its unique biomarker signatures in the diagnosis of Tuberculosis (TB), while introducing further unique combinations of biomarkers that can provide accurate information for the diagnosis of the disease. This patent was critically informed by the results generated from the completion of screening of large cohorts of clinical samples sourced from clinical studies commissioned by ProteinLogic, and from a successful Freedom-to-Operate study performed by the company in June 2018.

With a granted patent, and another, expanded patent under review, ProteinLogic is now well positioned to enter the market in diagnostics for TB, disrupting the current standard-of-care, and making an impact in the fight against this terrible disease.

ProteinLogic Appoints Dr Edward Gibson as Non-Executive Director

CAMBRIDGE, UK (2018-09-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Edward Gibson as Non-Executive Director.

Dr Gibson holds a holds a degree in Chemistry from Bristol University, and a PhD in Biochemistry from Oxford University, where he also performed postdoctoral research. Since then, he has held a number of senior leadership roles with Bristol-Myers Squibb, focusing on commercialization and lifecycle management within the company’s oncology department, rising to becoming a member of the European oncology steering committee. He then went on to become Senior Director for New Product Strategy and EU commercialization with AVEO, as a member of the senior executive team. Since 2013, he has held the role of Global Pharma Key Opinion Leader for the Korean Health Industry Development Institute, and has devoted himself in the development of solutions to complex issues in healthcare access a CEO of an independent consultancy.

Dr Gibson commented: “Joining the board at this critical time in the development of ProteinLogic is an extremely exciting opportunity. I am looking forward to working with the diverse and knowledgeable team members in developing and delivering credible, commercial diagnostic solutions to complex disease problems. Starting with the acute need in identifying cases of Active Tuberculosis.”

Dr Nicolas Huber, CEO of ProteinLogic, commented: “I am very excited to welcome Dr Gibson to the board of ProteinLogic. He brings a wealth of knowledge in the biotech industry, including in markets in which ProteinLogic has keen interest. With his extensive expertise in the commercialization of novel products in the field, he will be instrumental in helping the company define the most direct and profitable routes to market for our unique Immiprint diagnostic for the ruling-out of Active Tuberculosis, maximizing the value of our solution. Dr Gibson’s  joining strengthens the board of the company with unique commercial know-how that is of paramount importance to our success. I am personally very much looking forward to closely collaborating with him in the near future.”